ArticleMolecules and cells2026
E-cadherin-driven adherens junction reinforcement promotes spheroid-mediated invasion and progression in ALK-rearranged lung cancer chemoresistance.
Article in Molecules and cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis of cancer cells is driven by morphogenic changes that involve cytoskeletal remodeling and adherens junction reorganization. These cytoskeletal dynamics enable cancer cells to modulate their shape, adhesion, and motility, contributing to invasion, metastasis, and therapeutic resistance. In non-small cell lung cancer, anaplastic lymphoma kinase (ALK) gene rearrangements represent key oncogenic drivers, and ALK tyrosine kinase inhibitors such as crizotinib have significantly improved clinical outcomes. However, resistance frequently develops, often through on-target mutations or poorly understood bypass mechanisms. To investigate resistance-associated morphogenic adaptation, we employed two-dimensional and three-dimensional culture systems using crizotinib-resistant H2228 cells, along with transcriptomic profiling. The resistant cells formed compact, highly organized spheroids with upregulated E-cadherin expression and reinforced adherens junctions. This was accompanied by pronounced cytoskeleton-associated remodeling, characterized by enrichment of gene sets related to ruffle assembly, tissue morphogenesis, and the positive regulation of cell motility. Knockdown of E-cadherin disrupted spheroid architecture and partially restored crizotinib sensitivity, supporting its functional role in resistance. EpCAM was notably upregulated in peripheral protrusive cells and contributed to spheroid invasiveness in the resistant phenotype. Importantly, longitudinal biopsy samples from ALK-rearranged non-small cell lung cancer patients with cancer progression revealed elevated expression of E-cadherin and EpCAM during chemotherapy. It indicates the clinical relevance of adhesion-mediated morphogenic program impacting chemoresistance. Our findings suggest that bypass resistance is mediated, in part, by cytoskeleton-associated morphogenic plasticity that promotes spheroid formation, cell-cell adhesion, and invasive behavior. Targeting cytoskeletal remodeling and adherens junction dynamics may provide a novel therapeutic approach to overcome drug resistance in metastatic ALK-rearranged lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.